Prednisolone maintenance dose in relation to starting dose in the treatment of polymyalgia rheumatica and temporal arteritis: A prospective two-year study in 273 patients

Scandinavian Journal of Rheumatology

Volumn 30, Issue 5, 2001, Pages 260-267

  Myklebust, G ^a   Gran, J T ^a  

^a Revmatologisk avdeling   (Norway)

Author keywords

Polymyalgia rheumatica; Prednisolone; Temporal arteritis

Indexed keywords

CORTICOSTEROID; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; TEMPORAL ARTERITIS; TREATMENT OUTCOME;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; POLYMYALGIA RHEUMATICA; PREDNISOLONE; PROSPECTIVE STUDIES; TEMPORAL ARTERITIS; TREATMENT OUTCOME;

EID: 0034769883     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/030097401753180327     Document Type: Article

References (26)

1. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: Clinical and laboratory manifestations at onset of disease and at the time of diagnosis
2. Giant cell arteritis and polymyalgia rheumatica
3. Current therapy of polymyalgia rheumatica
4. Polymyalgia rheumatica and temporal arteritis: A retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients)
5. Prevention of blindness in giant cell arteritis by corticosteroid treatment
6. Corticosteroid requirements in polymyalgia rheumatica
7. Polymyalgia and giant cell arteritis
8. Polymyalgia rheumatica and corticosteroids: How much for how long?
9. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, South Norway: A prospective study 1987-94
10. The incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis: A prospective study of 231 cases
11. An evaluation of criteria for polymyalgia rheumatica
12. Polymyalgia arterica
13. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
14. Treatment of polymyalgia rheumatica
15. Long-term corticosteroid treatment in giant cell arteritis
16. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months
17. Treatment of polymyalgia rheumatica: Lower initial dose
18. Polymyalgia rheumatica, duration of therapy and long term outcome
19. The clinical and laboratory course of polymyalgia rheumatica/giant cell arteritis after the first two months of treatment
20. Temporal arteritis and polymyalgia rheumatica. Clinical and biopsy findings
21. Polymyalgia rheumatica and giant cell arteritis: Seven year study
22. Restricted dose and duration of corticosteroid treatment in patients with polymyalgia rheumatica and temporal arteritis
23. Clinical outcome of 149 patients with polymyalgia rheumatica and giant cell arteritis
24. Polymyalgia rheumatica without significantly increased erytrocyte sedimentation rate. A more benign syndrome
25. Polymyalgia rheumatica in patients with normal erythrocyte sedimentation rate
26. Polymyalgia rheumatica with low erythrocyte sedimentation rate at diagnosis